Drug-loaded nanoparticles have been widely researched in the antitumor. However, some of them are unsatisfactory in the long blood circulation and controlled drug release. Red blood cell (RBC) membrane vesicles (RV)-coated nanoparticles have gained more and more attention in drug delivery for their many unique advantages, such as excellent stability, long blood circulation, and reduced the macrophage cells uptake. Herein, by utilizing the advantages of RV, we fabricated RV-coated poly (lactide-co-glycolide) (PLGA)-docetaxel (RV/PLGA/DTX) nanoparticles to enhance the antitumor efficiency in vivo. The RV/PLGA/DTX showed spherical morphology with particle size of about 100 nm and zeta potential at À12.63 mV, which could maintain stability for a long time. The RV/PLGA/DTX significantly enhanced cellular uptake of DTX compared to PLGA/DTX in HepG2 cells. Moreover, RV/PLGA/DTX showed the strongest antitumor effect in vitro. Prolonged blood circulation and enhanced DTX accumulation at the tumor site through enhanced permeability and retention (EPR) effect were achieved by RV/PLGA/DTX, which eventually obtained satisfactory antitumor effect and depressed system toxicity on mice bearing HepG2 xenografts mouse models when compared with free DTX. The hematoxylin and eosin (H&E) and immunofluorescence assays further proved the advantages of RV/PLGA/DTX in vivo antitumor. These RV-coated nanoparticles provide a mimetic therapy, completely inhibited the growth of the HepG2 cells, and with simple compositions, suggesting it to be an ideal strategy for improving the antitumor effect of drug-loaded nanoparticles.
Introduction
Hepatocellular carcinoma (HCC) is one of the major health problems worldwide. 1 Surgical resection is still the major treatment for HCC; however, it is useless for patients with multiple or metastatic HCC. 2 For these patients, chemotherapy becomes the most important currently available treatment. However, it is regrettable that most chemotherapies for HCC will cause disappointing effects, some of which are life-threatening. 3 Therefore, it is urgent and important to search for effective chemotherapeutic agents to reduce the risk of side effects and improve the treatment effects for patients with advanced or recurrent HCC.
Over the past several years, researchers have made a great effort in drug delivery systems to reduce the side effects of chemotherapy drugs and improve their treatment effects. They can be divided into two categories: receptor-mediated nano-drug delivery system (RMDDS) and environment-sensitive nano-drug delivery system (ESDDS). 4 However, both of these two methods have clear disadvantages. For example, RMDDS often faces premature drug leakage from this system in vivo, 5 while the ESDDS often faces inefficient cellular uptake of the drugs. Therefore, it is very necessary to fabricate an ideal drug delivery system to depress the premature drug leakage and increase the cellular uptake of chemotherapeutic drugs.
Recently, progresses in drug delivery systems based on biodegradable polymer nanoparticles have attracted more and more attention. Nanoparticles of biodegradable copolymers are emerging as a promising drug delivery platform for cancer treatment. 6, 7 In particular, poly(lactide-co-glycolide) (PLGA) polymer, approved by the United States Food and Drug Administration, has been widely researched for drug delivery. 8, 9 The rapid development of new engineering strategies has urged researchers to combine nanoparticles with natural membranes to create natural-inspired mimetic drug delivery systems. 10 The fabricated mimetic systems possess both the physicochemical properties of synthetic nanomaterials and the functional cell membranes. 11 Among various cell membranes, red blood cell (RBC) membrane vesicles (RV) has obtained extraordinary attention due to its unique advantages, such as noimmunogenicity and abundant "self-markers" on the membrane surfaces. 12 For example, CD47 has been identified on RBC surfaces as a self-marker that actively signals macrophages and prevents their uptake. Through a well-established topdown method, the RV could perfectly coat onto the surface of nanoparticle to inherit the functions. 13 The RVcoated nanoparticles own many advantages compared to single nanoparticles, including protecting cargoes for long blood circulation, remarkable biocompatibility, reduced macrophage cells uptake, and enhanced cancer cellular uptake. 12 All these advantages of RV inspired us to associate it with nanoparticles for efficient drug delivery.
Herein, we designed RV-coated docetaxel (DTX)-loaded PLGA nanoparticles (RV/PLGA/DTX) with decreased premature DTX release and enhanced tumor cellular uptake (Scheme 1). After coated with RV, the RV/PLGA/DTX could maintain excellent stability in vitro. In addition, the DTX release of RV/PLGA/ DTX was obviously slow down and the cellular uptake was increased compared to PLGA/DTX in vitro. We hypothesize that the RV could stabilize PLGA/DTX in blood circulation, prevent the encapsulated DTX from leakage, and enhance the tumor cellular uptake in vivo. In the HepG2 xenografts mouse models, the RV/PLGA/DTX exhibited more significant tumor suppression and higher safety compared to free DTX. Moreover, the RV/PLGA/DTX could cause more apoptosis in tumor tissue, which was validated by the hematoxylin and eosin (H&E) and immunofluorescence assays. All the results indicated that the RV mimetic DTX-loaded PLGA nanoparticles could integrate the advantages of RV and nano-drug delivery systems to completely suppress the HCC.
Experimental section

Materials
Carboxy-terminated 50:50 PLGA polymer (MW 15 kDa) was obtained from PolySciTech Co., Ltd (Indiana, USA). Docetaxel (DTX) was purchased from Aladdin, China. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and fluorescein isothiocyanate (FITC) were all purchased from Sigma-Aldrich, USA. Dubelcco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were provided by Gibco BRL (Carlsbad, CA, USA). Caspase-3 antibodies were obtained from Abcam Company (Cambridge, UK). Distilled deionized water was produced with a Milli-Q water purification system (Millipore Co., Billerica, MA, USA).
Preparation of DTX-loaded PLGA nanoparticles
PLGA/DTX nanoparticles were prepared through a double emulsion solvent evaporation method. In briefly, DTX (20 mg) was dissolved in 4 mL of 0.001 N HCl and then were slowly added into 4 mL of PLGA solution in DCM (25 mg/mL). The mixed solution was emulsified using a high-shear rotor homogenizer (Ultra-Turrax T18 Basic, IKA, Germany). After that, the obtained emulsion was slowly added into 40 mL of 0.01 M phosphate buffer containing 1% aqueous solution of PVA and stirred at room temperature for 12 h. Then the obtained mixed solution was passed through a high-pressure homogenizer (Panda Plus2000, GEA Niro Soavi, Italy) at 1000 bar. The organic solvent in the solution was removed by evaporating in vacuum. At last, the DTX-loaded PLGA nanoparticles were obtained by lyophilisation and stored at 4 C.
Preparation of RBC membrane-derived vesicles
RV were prepared using a procedure previously reported. 12 In brief, fresh whole blood collected from female imprinting control region (ICR) mice (6-8 weeks) obtained from the Animal Center at Jilin University was centrifuged at 800 rcf for 5 min at 4 C to remove the plasma and the buffy coat. Then the resulting RBCs were washed by ice cold 1 Â phosphate buffer saline (PBS) for three times. After that, the washed RBCs were resuspended by 1/4Â PBS, kept in an ice bath for 60 min, and subsequently centrifuged at 800 rcf for 5 min. The light-pink sedimentary ghosts were collected and washed with 1Â PBS for three times. The resuspended ghosts were sonicated for 300 s at 53 kHz and power of 100 W. Sequentially, the ghosts were extruded through 400 and 100 nm polycarbonate membranes with an Avanti mini extruder (Avanti Polar Lipids) to prepare the final RV.
Preparation of RV-coated DTX-loaded PLGA nanoparticles
To prepare RV/PLGA/DTX, RVs were fused onto the surface of PLGA/DTX and 1 mg of PLGA/DTX was mixed with 300 lL of whole blood and then extruded 10 times through a 100 nm polycarbonate porous membrane with an Avanti mini extruder for complete particle coating. The resulting RV/PLGA/DTX was carefully centrifuged and the excess membrane components remaining in the supernatant were removed.
Characterization of the DTX-loaded nanoparticles
Particle size, zeta potential, and surface morphology. Particle size and zeta potential of PLGA/DTX and RV/PLGA/ DTX was determined by a Malven zetasizer ZEN3690 analyzer (Malven, UK). The morphological examination of PLGA/DTX and RV/PLGA/DTX was performed under transmission electron microscopy (TEM) (H-600, Hitachi, Japan).
DTX encapsulation efficiency and loading capacity. For determining the drug-loading content (DLC) and drug-loading efficiency (DLE) of PLGA/DTX, 1 mg PLGA/DTX nanoparticles were dissolved in 1 mL DMSO and stirred for 10 h at room temperature.
The concentration of DTX was determined spectrophotometrically at k max of 230 nm in UV Visible spectrophotometer (Cintra-10 GBC UV Visible spectrophotometer, Japan). The ultraviolet absorption value of blank PLGA was measured for correction. The measurement was performed in triplicates. The DLC and DLE of PLGA/DTX were calculated.
Stability assays. The stability of RV/PLGA/DTX in PBS at pH 7.4, 25 C, was tested by dynamic light scattering (DLS) at different time points.
In vitro DTX release. The in vitro drug release study of DTX from PLGA/DTX and RV/PLGA/DTX nanoparticles were evaluated in PBS at pH 7.4. The nanoparticles were suspended in PBS at the concentration of 0.1 mg/mL. The solutions were transferred into dialysis bags (MWCO ¼ 1000 Da). The dialysis bags were then put into a beaker and followed by incubation in 100 mL of PBS at 37 C with continuous shaking of 70 r/min (model I2400, New Brunswick Scientific, Edison, NJ). At predetermined time intervals, 1.5 ml of PBS was taken out and another 1.5 mL fresh PBS was added. The amount of released DTX was determined spectrophotometrically at k max of 230 nm in UV Visible spectrophotometer (Cintra-10 GBC UV Visible spectrophotometer, Japan).
Cell experiments
Cell culture. The human hepatoma cell line (HepG2, ATCC) were cultured in DMEM supplemented with 10% FBS at 37 C in a 5% CO 2 /95% air humidified environment incubator (Thermo HERAcell, USA).
Flow cytometry. Flow cytometry (FCM) was used to determine the cellular uptake rates of PLGA/DTX and RV/PLGA/DTX after 2 h of culture. Fluorescent formulations were fabricated by incorporating PLGA-FITC instead of PLGA in the formulations as described in Preparation of DTX-loaded PLGA nanoparticles section. In brief, 200,000 HepG2 cells were seeded in sixwell cell culture plates per well and cultured for 24 h. Then, PLGA/DTX and RV/PLGA/DTX were added into each well with final DTX concentrations of 20 lg/mL. Free FITC treated and untreated cells were used as control. After 2 h incubation, the medium was removed, and the samples were washed with PBS three times. Cells were then harvested with trypsin, centrifuged at 1000 r/min for 5 min at 25 C. The bottom cells were resuspended with PBS to a final cell concentration of 500,000 cells/mL. Data were analyzed by a flow cytometer (Beckman, CA, USA).
Cell viability assay. The cytotoxicities of free DTX, PLGA/DTX, and RV/PLGA/DTX with a DTX concentration from 0.31 to 10 lg/mL were determined toward HepG2 cells by an MTT assay. In brief, HepG2 cells were planted into 96-well plate at the density of 8000 cells per well and incubated for 24 h to allow cell attachment. After that, the cells were incubated with various DTX formulations for 24 h. Cells incubated with the culture medium were used as negative control. Subsequently, the medium was replaced with DMEM containing MTT (5 mg/mL), and the cells were further incubated at 37 C for 4 h. After that, the MTT solution was removed, and 100 lL of DMSO was added to each well. The plates were vibrated for 10 min and measured at 490 nm using a microplate reader (Thermo, USA). The cell viability of the control cells was taken 100% and used to calibrate that of the drug treated cells. The experiments were performed in sixplicate. Graphpad Prism statistical analysis software was used for IC 50 calculating.
In vivo antitumor efficacy and histology analysis
In vivo tumor growth inhibition was performed to evaluate the antitumor efficacy of free DTX, PLGA/DTX, and RV/PLGA/DTX. In brief, five-week-old female BALB/C nude mice (n ¼ 10, 14-18 g) were purchased from the Experimental Animal Center of Jilin University (Changchun, P.R. China)
, the mice were randomly divided into four groups (n ¼ 10 for each group): normal saline (NS) as a control, free DTX, PLGA/DTX, and RV/PLGA/DTX. Subsequently, mice were intravenously administered with 0.2 mL NS, free DTX, PLGA/DTX, and RV/PLGA/ DTX (DTX dose of 5 mg/kg) for four times with a three-day interval. The tumor sizes and body weights were monitored every other day. The tumor volume was calculated with the formula: volume (mm
. The tumor inhibition ratio was calculated with the formula: Tumor inhibition rate (%) ¼ (Vcontrol À Vsample)/Vcontrol Â 100. At the end of treatments, all the mice were sacrificed; heart, liver, spleen, lung, kidney, and tumor were immediately excised, washed with normal saline, and then fixed with 4% formalin and stained by H&E to observe the systemic toxicity of all the DTX formulations. The paraffin sections were imaged by a fluorescence microscope (Olympus, Japan). The tumors were then subjected to caspase-3 assay for the intratumoral apoptosis evaluation. Images were observed by CLSM.
Statistical analyses
All experiments were carried out at least three times. All the data were expressed as means AE standard deviation (SD) unless otherwise indicated and analyzed for statistical significance using SPSS (Version 13.0, SPSS Inc., Chicago, IL, USA). Multigroup comparisons of the means were carried out by one-way analysis of variance (ANOVA) test with post hoc contrasts by Student-Newman-Keuls test. A probability (P) less than 0.05 was considered statistically significant.
Results and discussion
Preparation and characterization of RV/PLGA/DTX
The DLE and DLC of RV/PLGA/DTX was 8.2% and 96.5%, respectively. The hydrodynamic diameter of the PLGA/DTX was 88.5 nm (polydispersity index (PDI) ¼ 0.121) and increased to 104 nm (PDI ¼ 0.119) after RV coating (Figure 1(a) ). The thickness of the RV was determined to be about 8 nm, which was consistent with that of the RBC membranes in the previous reports.
14 This result suggested the successful fusion of RV on the surface of PLGA/DTX. The successful coating of RV onto the surface of PLGA/DTX was further confirmed by transmission electron microscope (TEM) examination. As shown in Figure 1(b) , the PLGA/DTX was shown clear spherical morphologies, and the RV/PLGA/DTX showed a clear core-shell structure, which indicated the successful coating of RV onto the surface of PLGA/DTX. It should be noted that the size of RV/PLGA/DTX (around 100 nm) was appropriate to the selective accumulation in the tumor through the enhanced permeability and retention (EPR) effect. 15, 16 In addition, the zeta potentials of PLGA/DTX, RV, and RV/PLGA/DTX were shown in Figure 2 , the zeta potential of RV/PLGA/DTX was changed to À12.63 mV, comparable to that of RV (À12.49 mV) and PLGA/DTX (14.58 mV). These results also suggested the RV was successfully coated onto the surface of PLGA/DTX.
The long-term stability of RV/PLGA/DTX was characterized by the change of particle size over two weeks. As shown in Figure 3 , the particle size of RV/PLGA/DTX had no obvious changes. This result indicated that RV-coated PLGA/DTX had good stability. The good stability will make it keep stable structure in the in vivo circulation.
Then the in vitro DTX release behaviors of PLGA/ DTX and RV/PLGA/DTX in PBS (pH ¼ 7.4) at 37 C were investigated ( Figure 4 ). As shown, PLGA/DTX exhibited a fast DTX release profile, with 35.2% cumulative release within 12 h and 45.1% after 72 h. This result indicated the relatively instability of PLGA/ DTX in physical medium. As a contrast, after coating with RV, RV/PLGA/DTX showed a good stability with negligible drug release over 72 h. This result indicated that RV wrapping could reduce the DTX release to a certain extent. This is very important for its efficient drug delivery in the tumor sites in vivo.
Cellular uptake in vitro
The cellular uptakes of free FITC, PLGA/DTX, and RV/PLGA/DTX on HepG2 cells were determined by FCM. As shown in Figure 5 , HepG2 cells without any treatments were used as blank control, which showed only the autofluorescence of cells. Meanwhile, the fluorescence intensity of cells co-cultured with free FITC was higher than those of PLGA/DTX and RV/PLGA/ DTX at the time point of 2 h. This might be due to that the cellular uptake pattern of free FITC by diffusion was faster than that of DTX-loaded nanoparticles by endocytosis. 17 In addition, the FITC fluorescence intensity of RV/PLGA/DTX was higher than that of PLGA/DTX. A possible explanation for the improved cellular uptake of RV/PLGA/DTX than PLGA/DTX might be proposed based on the unique fluidity of the coated membrane. 18 The elevated cellular uptake of RV/PLGA/DTX will be propitious to its in vivo antitumor activity.
In vitro cytotoxicity assay
The in vitro cytotoxicity of all the DTX formulations was evaluated by an MTT assay. The cellular proliferation inhibition capability of free DTX, PLGA/DTX, and RV/PLGA/DTX were compared. Cells were treated with various concentrations of different DTX formulations for 24 h. As shown in Figure 6 , PLGA/ DTX exhibited higher cytotoxicity over free DTX after incubation for 24 h, which was probably due to the enhanced stability and sustained release of DTX following its encapsulation in nanoparticles. 19 Noticeably, RV/PLGA/DTX exhibited more effective proliferation inhibition effects on HepG2 cells than PLGA/DTX. This might be due to the enhanced cellular endocytosis of RV/PLGA/DTX than PLGA/DTX, and the greater stability of RV/PLGA/DTX meant the less extracellular drug release. As a result, a greater amount of DTX was internalized into the tumor cells by endocytosis and sustained DTX release in tumor cells effectively. Moreover, the half maximal inhibitory concentrations (IC 50 ) of free DTX, PLGA/DTX, and RV/PLGA/ DTX were calculated to be 1.11, 0.69, and 0.43 lg/ mL, respectively. These results indicated that RV/PLGA/DTX could enhance the cytotoxicity of DTX in HepG2 cells obviously.
In vivo antitumor efficacy measurement
The antitumor efficacy of RV/PLGA/DTX was investigated in nude mice bearing HepG2 tumors and compared with that of free DTX and PLGA/DTX. Mice were randomly divided into four groups. When the tumor volume reached about 50 mm 3 , mice were intravenously administered with different formulations at a DTX dose of 5 mg/kg every four days for four consecutive injections. The changes of tumor volumes and tumor weights were recorded every other day until the 17th day. Animals received saline were used as control. As shown in Figure 7 (a), tumors treated with saline grew rapidly, the tumor volume of which was 1.5-, 2.5-, and 4.8-fold of free DTX, PLGA/DTX, and RV/PLGA/DTX at day 17, respectively. The free DTX showed a weak antitumor efficacy with a tumor volume reduction of 33.9% compared to the control group. The PLGA/DTX exhibited modest antitumor effect, with tumor inhibition rate of 60.0%.
Interestingly, the RV/PLGA/DTX led to an obvious suppression of the tumor growth. At the end of the treatment, the tumor volume was only 351.78 mm 3 , which indicated the important role of RV coating in the antitumor. The outstanding antitumor efficacy of RV/PLGA/DTX could be attributed to the successful coating of RV onto the surface of PLGA/DTX, which decreased the clearance, enhanced the accumulation, and triggered tumor diffusion. 18, 20 The change of body weight is an important indicator for the evaluation of DTX induced system toxicity. As shown in Figure 7 (b), free DTX showed rapidly decreased body weights and reduced about 5.9% of their initial weight at the end of experiment. Correspondingly, other treatment groups showed stable increased body weights, which indicated the low systemic toxicity of these formulations.
The histological analysis of tumor apoptosis and necrosis was performed by the H&E assay, and the mechanism of the antitumor effect of RV/PLGA/ DTX was further exploited by caspase-3 staining of excised tumors. As shown in Figure 8 , normal saline group exhibited intact nuclei morphology, which indicated negligible apoptosis or necrosis in the tumor. Conversely, free DTX, PLGA/DTX, and RV/PLGA/ DTX groups showed various apoptosis or necrosis. Notably, RV/PLGA/DTX group had the completely nuclei deficient in the tumor slices. The fluorescence staining of caspase-3 further confirmed the results. The apoptotic degree of different groups was consistent with that of the tumor inhibition rate. In detail, no obvious apoptosis fluorescence signal was observed in normal saline group. Free DTX group exhibited certain apoptosis fluorescence, PLGA/DTX group exhibited considerable apoptosis, while the RV/PLGA/DTX group exhibited the maximum degree of apoptosis fluorescence. The results of H&E and immunofluorescence assays further indicated the efficient suppression of tumor growth of RV/PLGA/DTX. The biocompatibility and decreased systemic toxicity of RV/PLGA/DTX was further confirmed by the H&E histological analysis of the main organs (i.e., heart, liver, spleen, lung, and kidney). As shown in Figure 9 , the free DTX caused severe heart damage, as confirmed by the myocardial fiber breakage, neutrophils accumulation, and apoptosis in the H&E images. In contrast, the cardiomyocytes treated with PLGA/DTX and RV/PLGA/DTX lined in order, and sarcolemma kept integrity. Moreover, the free DTX also caused inflammatory infiltrates in the liver, including the neutrophils accumulation and microregional necrosis. However, the changes in the PLGA/DTX and RV/PLGA/DTX treatment groups were less obvious. The decreased organic toxicity of PLGA/DTX and RV/PLGA/DTX might be contributed to the decreased DTX release from the nanoparticles during the blood circulation. Moreover, the minimized immunoreaction and RES uptake of RV/PLGA/DTX owing to the RV coating were also played an important role. 13 The H&E histological analysis consistently confirmed the low system toxicity of RV/PLGA/DTX and suggested the potential application of it in clinic.
Conclusion
In summary, we fabricated RV-coated DTX-loaded PLGA nanoparticles with increased cellular endocytosis, tumor-specific drug release, and reduced system toxicity. The RV/PLGA/DTX exhibited a superior size for the EPR. The coated RV could obviously enhance the colloidal stability of PLGA/DTX and prevent the encapsulated DTX from premature release in vivo. Moreover, the RV/PLGA/DTX showed enhanced cellular uptake of DTX than PLGA/DTX and free DTX and therefore exhibited more excellent antitumor in vitro. In a HepG2 tumor model, the RV/ PLGA/DTX exhibited a significantly enhanced antitumor efficiency and a lower systematic toxicity compared to either PLGA/DTX or free DTX at an equivalent DTX dose. All these results demonstrated the advantage of RV-coated nanoparticles in vivo application. Apparently, the RV/PLGA/DTX provided new insights for the optimization of drug-loaded nanoparticles for antitumor in vivo. With convenient fabrication, mimetic structure, and satisfactory antitumor efficiency, the RV/PLGA/DTX could provide a solution for the current predicament of drug-loaded nanoparticles in antitumor.
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